Glaukos Corporation (GKOS) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $139.66: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality; Rich valuation.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company offering MIGS devices (iStent family) and procedural pharmaceuticals (iDose TR) for glaucoma, plus corneal health therapies (Photrexa, Epioxa) for keratoconus, sold to ophthalmologists globally.... Read more
Sell if holding. Engine safety override at $139.66: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.
Passes 5/6 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierSan Clemente sole manufacturing location10-K Item 1A: 'Our sole manufacturing location for our iStent and iDose products is an approximately 120,000 square foot campus located in San Clemente, California'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·2 ceiling hits
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -37.0%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $139.66: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10. Specifically: Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $129.49. Score 5.5/10, moderate confidence.
Take-profit target: $142.34 (+2.2% upside). Prior stop was $129.49. Stop-loss: $129.49.
Concentration risk — Supplier: San Clemente sole manufacturing location; Target reached (-12.4% upside); Quality below floor (3.9 < 4.0).
Glaukos Corporation trades at a P/E of N/A (forward 243.6). TrendMatrix value score: 2.6/10. Verdict: Sell.
22 analysts cover GKOS with a consensus score of 4.2/5. Average price target: $140.
What does Glaukos Corporation do?Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company offering MIGS devices (iStent...
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company offering MIGS devices (iStent family) and procedural pharmaceuticals (iDose TR) for glaucoma, plus corneal health therapies (Photrexa, Epioxa) for keratoconus, sold to ophthalmologists globally. iStent and iDose products are manufactured exclusively at a single campus in San Clemente, California.